Table 2.
Anticancer activity against a panel of approximately sixty tumor cell lines from nine different cancer types at 10-fold dilutions of five concentrations.
| Compound | End point (μM) | Leukemia | NSC lung cancer | Colon cancer | CNS cancer | Melanoma | Ovarian cancer | Renal cancer | Prostate cancer | Breast cancer | MG_MID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4d | GI50 | 3.28 | 7.91 | 5.73 | 7.57 | 8.07 | 11.37 | 8.13 | 4.64 | 6.50 | 7.02 |
| TGI | 25.31 | 42.06 | 21.01 | 24.10 | 28.21 | 79.20 | 44.04 | 31.40 | 47.30 | 38.07 | |
| 4f | GI50 | 2.14 | 3.52 | 3.53 | 4.09 | 4.08 | 9.79 | 4.66 | 4.61 | 2.99 | 4.38 |
| TGI | 7.38 | 61.59 | 63.20 | 31.99 | 45.88 | 79.83 | 53.25 | 100.0 | 15.85 | 50.99 |